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Abstract
Background—Observational studies suggest there are differences in adherence to
antihypertensive medications in different classes. Our objective was to quantify the association
between antihypertensive drug class and adherence in clinical settings.
Methods and Results—Studies were identified through a systematic search of English-
language articles published from inception of computerized databases till February 1, 2009.
Studies were included if they measured adherence to antihypertensives using medication refill data
and contained sufficient data to calculate a measure of relative risk of adherence and its variance.
An inverse-variance weighted random-effects model was used to pool results. Hazard ratios (HR)
and odds ratios (OR) were pooled separately, and HRs were selected as the primary outcome.
Seventeen studies met inclusion criteria. The pooled mean adherence by drug class ranged from
28% for beta-blockers to 65% for angiotensin II-receptor blockers (ARBs).There was better
adherence to ARBs compared to angiotensin-converting enzyme inhibitors (ACEIs) (HR 1.33,
95%CI 1.13–1.57), calcium channel blockers (HR 1.57, 95% CI 1.38–1.79), diuretics (HR 1.95,
95%CI 1.73–2.20), and beta-blockers (HR 2.09, 95%CI 1.14–3.85). Conversely, there was lower
adherence to diuretics compared to the other drug classes. The same pattern was present when
pooling studies that used ORs. When accounting for publication bias, there were no longer
significant differences in adherence between ARBs and ACEIs or between diuretics and beta-
blockers.
Conclusion—In clinical settings, there are important differences in adherence to
antihypertensives in separate classes with lowest adherence to diuretics and beta-blockers and
highest to ARBs and ACEIs. Yet, adherence was suboptimal regardless of drug class.
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Introduction
Hypertension is the most common chronic illness in developed countries and one of the
most important risk factors for cardiovascular disease.1 Numerous studies have shown that
blood pressure lowering is associated with major reductions in coronary events, strokes, and
mortality.2, 3 While counseling about lifestyle factors plays a role, prescribing
antihypertensive medications remains the cornerstone of the medical management of
hypertension.4
Clinical practice guidelines, such as the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of Hypertension (JNC7)5, have been
developed to assist clinicians with their selection of antihypertensive medications. These
guidelines rely heavily on data from clinical trials to inform their preferences for
antihypertensive medications. Yet, as a result of selection bias, run-in periods, and behavior
reinforcement through close follow-up, adherence to medication in clinical trial settings may
not be representative of adherence in “real world” settings.6 For example, in the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),
the level of adherence to treatment at 1 year ranged from 83% to 88% depending on drug
class.7 In observational studies, adherence to antihypertensive medications is typically much
lower.8 Accordingly, clinical trials such as ALLHAT may underestimate the impact of
differences in adherence to medications from separate drug classes in clinical settings.
The literature describing the association between antihypertensive drug class and adherence
is characterized by a wide variety of patient populations, drug class comparisons, and
definitions of adherence. This heterogeneity has made it difficult to draw conclusions about
the clinical relevance of differences in adherence according to drug class. Quantifying the
overall impact of drug class on adherence in observational settings would provide important
evidence to guide the selection of blood pressure medications as well as to guide adherence
monitoring. Accordingly, we performed a meta-analysis to determine the impact of
antihypertensive drug class on adherence to blood pressure medications.
Methods
Data Sources and Searching
This study was performed as part of a larger systematic review of predictors of adherence to
oral cardiovascular and diabetic medications. The research methodology was done in
accordance with MOOSE guidelines.9 With the assistance of a medical librarian (L.F.),
potentially relevant articles were identified by searching publicly available computerized
databases. The search included all articles and abstracts (including unpublished doctoral
theses) referenced from database inception to February 1, 2009 in MEDLINE, Database of
Abstracts of Reviews of Effects, National Health Service Economic and Evaluation
Database, Health Technology Assessment Database, EMBASE, and PsycINFO. All relevant
subject heading and free text terms for adherence or compliance and for both the generic
class of drug [e.g., beta-blocker (BB), angiotensin-converting enzyme inhibitor (ACEI)] and
the individual names of antihypertensive medications, generic and proprietary, were
included (Appendix 1). Due to the large volume of literature on this topic, a set of
methodological filters was applied to the search strategies of the larger databases
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(MEDLINE, EMBASE and PsycINFO). Follow-up searches were performed by hand-
searching bibliographies from selected articles.
Study Selection
Articles were eligible for inclusion if they were published in English and include community
dwelling patients 18 years of age and older. Eligible study designs included observational
cohorts in which adherence to antihypertensive medication was evaluated as an outcome. To
reduce heterogeneity when pooling studies, studies were only eligible if they measured
adherence using medication refill data. Articles also had to include data that compared
adherence between at least two distinct antihypertensive drug classes, and had to report
sufficient data to calculate a measure of relative risk of adherence and its variance.
A number of sociodemographic characteristics, medical and psychological conditions, and
regimen complexity qualities have been shown to influence adherence.10, 11 Accordingly,
studies were excluded if they did not consider at least one potentially confounding
characteristic in their analyses of the association between drug class and adherence. Studies
in which adherence was measured by determining whether patients were using a medication
at a single time-point were also excluded as this was not equivalent to studying adherence
with a regimen over time. For the remaining studies, we assigned a quality rating using a
checklist adapted from the recommendations of the International Society of
Pharmacoeconomics and Outcomes Research (ISPOR)(Appendix 2).12, 13
Two investigators (D.M., I.K.) independently reviewed all citations identified through the
literature search using a predefined protocol. Articles that clearly did not meet inclusion
criteria were excluded at the title and abstract level. The remaining articles were selected for
full text review. When limited information was available from the abstract, full text was
always obtained. Included articles underwent a quality assessment by two investigators
(Z.S., I.K.). Disagreements regarding the selection and quality assessment of articles were
resolved through discussion and full consensus was achieved at each stage of review.
Data Extraction
Two investigators (Z.S., I.K.) independently extracted data from selected studies using a
standardized form. Information was collected regarding dates and sizes of the studies; types
of patients enrolled; duration of follow-up; types of drug classes assessed; whether patients
were concurrently taking antihypertensive medications from other drug classes; the
proportion initiating ARBs; and whether the study had any pharmaceutical industry
affiliation. Pharmaceutical affiliation was ascribed if the study received funding from a
pharmaceutical company or if a study author was employed or served as a consultant for the
industry. Adherence data pertaining to combination antihypertensive pills were not
extracted.
Investigators also recorded the method used to define adherence; the mean adherence
according to drug class; the measure of the relative risk of adherence between pairs of drug
classes; and the types of covariates included in adjusted analyses. In accordance with ISPOR
guidelines14, we defined adherence as an umbrella term that encompasses two related
categories of pill-taking behavior: compliance and persistence. Adherence was categorized
as compliance if it measured the proportion of days covered (PDC) with medication,
calculated as the sum of the days’ supply for all prescriptions filled during the study time
period divided by the total number of days in this time period. Individuals were then defined
as compliant or non-compliant using a threshold of 80% for PDC. Adherence was
categorized as persistence if it referred to either 1) a continuous measure of the number of
days on a given antihypertensive from initiation of therapy to the end of the last supplied
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prescription in the study period before a significant gap in coverage with the medication or
2) a dichotomous variable in which patients were categorized as persistent or non-persistent
depending on whether they had any significant gaps in coverage during the study period.
Persistence studies were sub-categorized according to whether they defined persistence as
medication persistence (time to discontinuation of a given medication) or therapy
persistence (time to discontinuation of all antihypertensive medication).13 Dichotomous
measures of adherence were used to calculate odds ratios (ORs) for adherence between two
drug classes using logistic regression. Continuous measures of adherence were used to
calculate hazard ratios (HRs) using Cox proportional hazards regression.
Data Synthesis and Analysis—Two pairs of studies15–18 included overlapping data,
and hence, two studies were excluded from quantitative analysis.15, 17 The remaining studies
were grouped for pooling according to comparisons of adherence between pairs of drug
classes. Data were then subgrouped according to whether the measure of relative risk was an
OR or HR. The pooled HR of adherence was selected as the primary outcome because 1)
this was the most frequently used measure of adherence in the pooled studies and 2) the HR
accounts for censoring and is thus the preferred measure of relative risk with prospective
data. ARBs and diuretics were selected as the primary basis for comparison as they were the
two drug classes with the most frequent pair-wise comparisons across studies. Individual
estimates of log relative risks were pooled using random effects meta-analysis with inverse
variance weighting in Stata, version 10 (College Station, TX). The i-squared statistic was
used to estimate the percentage of variability across studies that is attributable to
heterogeneity and was tested for deviation from zero. To test for sources of heterogeneity for
our primary outcome, we performed sensitivity analyses that compared pooled HRs
separately for articles in which adherence was defined as medication persistence and therapy
persistence. Similarly, we performed sensitivity analyses by stratifying articles according to
study size, study quality, country, and pharmaceutical affiliation. We used chi-square to test
for significance in these analyses and log transformed HRs to approximate normality. To
account for publication bias, we used the non-parametric “trim-and-fill” model.19 We used
this model when there were at least 3 studies available for pooling.
As a secondary means of comparing adherence between drug classes, we pooled the mean
percent adherence by individual drug class across studies that measured adherence as
persistence. We weighted our calculations according to person-months of exposure.
Results
Qualitative analysis (n=17)
The comprehensive search yielded 115 unique articles related to predictors of adherence to
antihypertensive medications.(Figure 1) Seventeen articles met inclusion
criteria.15–18, 20–32(Table 1) Five studies were rated ‘excellent’ and satisfied all of the
requirements on the quality checklist; twelve studies were rated ‘good’ and missed one or
two items on the checklist. Included articles assessed adherence to antihypertensive
medications between 1989 and 2004 for 935 920 patients. The studies measured adherence
using medication refill data either from insurance claims or pharmacy refills in closed
pharmacy systems in North American and Europe. Thirteen articles defined adherence as
persistence (5 medication persistence; 8 therapy persistence) and four articles defined
adherence as compliance. ARBs were the least likely drug class to be prescribed with rates
from 2 – 23%.
Articles had large differences in their selection of covariates for adjusted analyses.
Covariates included demographics (age, race, gender, income, ethnicity), burden of disease
(comorbidities), complexity of medication regimen (number of medications, frequency of
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dosing), health system barriers (insurance coverage, cost of care), health care utilization
(numbers of hospitalizations and physician visits), and prescriber characteristics (type of
physician).
Two articles provided data on overall compliance according to PDC.28, 32 In the study by
Zhang et al., 53% were compliant to antihypertensives (either an ACEI or ARB) and in the
study by Siegel et al., 78% to 84% were compliant. The mean overall persistence with
antihypertensives, available from 12 studies, ranged from 35% to 84%.
With respect to relative adherence, with one exception (Zhang et al.), there was better
adherence (p<.05) to ARBs compared to other drug classes studied (ACEI, CCB, BB,
diuretics), regardless of adherence definition.(Figure 2) Conversely, with two exceptions
(van Wijk-BC., BB comparison; Erkens et al., CCB comparison), there was lower adherence
to diuretics compared to other drug classes (p<.05).(Figure 3)
Quantitative analysis (n=15)
The pooled mean age of patients was 61.7 years, and 53.1% were female. The pooled mean
person-months of adherence observation across studies was 12.3 months. Using HR as the
primary measure of relative adherence, there was an increased risk of adherence to ARBs
compared to ACEIs (HR 1.33, 95%CI 1.13–1.57), CCBs (HR 1.57 95% CI 1.38–1.79), BBs
(HR 2.09 95% CI 1.14–3.85), and diuretics (HR 1.95 95%CI 1.73–2.20) (Figure 2). In
contrast, there was a lower risk of adherence to diuretics compared to all the other drug
classes (Figure 3). As a secondary analysis, four studies measured the relative risk of
adherence using ORs. The pattern of relative adherence remained the same using OR as the
measure of relative adherence with highest adherence to ARBs and lowest to diuretics and
beta-blockers (Figure 2, Figure 3).
Data were available for pooled estimates of adherence for individual drug classes from 9
studies, though 2 studies only contained data for 4 of the 5 drug classes which introduced
some between-study bias. The mean (95% CI) persistence to medication followed the
expected pattern with highest mean persistence to ARBs 64.9% (64.3% – 65.6%; and ACEIs
57.6% (57.2% – 57.9%); intermediate persistence to CCBs 52.0% (51.6% – 52.5%); and
lowest to BBs 28.4% (28.1% – 28.8%); and diuretics 51.0% (51.4% – 51.8%).
Overall, other than the comparison between ACEIs and ARBs, there was significant
heterogeneity when pooling data (i-squared statistic 91.7% to 98.0%). This supported the
use of the random effects model to estimate the relative risk of adherence between pairs of
drug classes. Given this substantial heterogeneity, we performed subgroup analyses for our
primary outcome to assess the impact of different definitions of adherence, study size,
quality, location, inclusion criteria, and pharmaceutical affiliation on the estimates of the
relative risk of adherence by drug class. All i-squared values were either reduced or
increased by less than 1% in subgroup analyses.
Subgroup analyses supported the robustness of the overall conclusions. First, we tested the
impact of defining adherence as medication persistence or as therapy persistence. The
definition of adherence did not change the overall pattern, with higher adherence to ARBs
compared to other drugs regardless of definition; however, the difference between ARBs
and ACEIs did not remain significant when restricting studies to those measuring adherence
as therapy persistence. Similarly, subgroup analyses involving study size, location, and
quality made no qualitative difference to the pattern of adherence with higher adherence to
ARBs compared to other drugs and lower adherence to diuretics compared to all other drugs,
though differences between diuretics and beta-blockers were not always statistically
significant. Thirteen studies restricted their inclusion of patients to those who were initiating
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a first medication for hypertension and were not concurrently prescribed any other
antihypertensives. There were no significant differences in the relationship between
adherence and drug class when the meta-analysis was limited to these studies. Sufficient
studies were available for testing the impact of pharmaceutical affiliation on relative
adherence in two instances. The relative benefit of adherence to ARBs versus ACEIs was
more pronounced (p =.006) in pharmaceutical-affiliated studies [pooled HR 1.41 (95% CI
1.17 – 1.70); 4 pooled studies] compared to non-pharmaceutical affiliated studies [HR1.09
(95%CI 1.06 – 1.11); 1 study]. There was no significant impact of pharmaceutical affiliation
on the estimate of relative adherence between ARBs and diuretics.
Publication bias affected the estimate of relative adherence according to HR in two
instances. There were no longer significant differences adherence between ARBs and ACEIs
[HR 1.10 (95%CI 0.94 – 1.30)] or between BBs and diuretics [HR1.13 (95% CI 0.89–1.44)]
after accounting for publication bias.
Discussion
We found that there was a significant relationship between adherence to antihypertensive
medication and drug class. When compared to patients prescribed diuretics and BBs, the
drug classes associated with the lowest adherence, patients prescribed ARBs were
approximately twice as likely to have good adherence. Overall, ACEIs appeared to have the
second best level of adherence, followed by CCBs, although insufficient data were available
for definitive ranking of pair-wise comparisons and publication bias may have accounted for
differences between ARBs and ACEIs.
There was a remarkable degree of consistency in the pattern of our results showing superior
adherence to ARBs and ACEIs and inferior adherence to diuretics and beta-blockers. No
single study dominated any of the pooled estimates and there was no substantial difference
in the pattern regardless of the adherence definition, or the size, quality, and location of the
study.
There are several possible reasons for these differences. Each of the drug classes is
associated with distinct side-effects. Diuretics, for example, can cause urinary frequency,
erectile dysfunction, fatigue, and muscle cramps.33 They can also produce metabolic and
electrolyte abnormalities that may lead physicians to discontinue them.
Another possible etiology for the differences in adherence by drug class may be variation in
provider and patient beliefs about medications. Perceived benefit of treatment is a core
component of several health behavior models34 and has been associated with adherence in
some studies of cardiovascular medications.35 Prior studies have shown differences in
physician perceptions of the effectiveness and tolerability of antihypertensive medication in
separate classes.36 Future studies might assess whether these differences mediate the
relationship between adherence and drug class.
The higher rate of adherence to ARBs compared to diuretics suggests that drug cost plays a
relatively minor role in antihypertensive adherence. It is possible that cost plays a more
significant role in under-insured populations in which medication users are responsible for a
significant portion of prescription costs; no articles were restricted to populations without
prescription insurance or with low socioeconomic status.
There are several limitations to our conclusions. First, ARBs were prescribed at lower rates
than are typical presently in developed countries. This may have biased the results
comparing ARBs to other drug classes. There may have been factors related to selection of
patients who are more adherent such that adherence to ARBs may be more related to patient
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selection factors rather than the properties of the drug class itself. Until this is assessed, it is
premature to recommend ARBs as first line medications for clinicians interested in
minimizing adherence problems. Second, these findings may not be generalizable to patients
who are already started on one or more antihypertensive medications. In practice, a growing
number of patients are on multiple BP medications and some guidelines even recommend
starting with combinations of drug classes for patients with BP markedly above goal.
Nevertheless, in our five studies which considered this question, the pattern of adherence
between drug classes was the same. Third, these analyses involved multiple statistical tests,
and thus the nominal type I error rate of 5% must be interpreted with caution. Fourth, there
was significant heterogeneity when pooling data. Still, the pattern of relative adherence
remained the same in subgroup analyses. Another limitation is that we excluded articles that
assessed adherence by drug class but did not report adjusted analyses of relative risks. A
qualitative review of these articles was consistent with the pattern of adherence found in our
meta-analysis. Finally, we did not have resources to review non-English language
publications nor to contact authors for unpublished data. Of note, one study of Korean
patients published after we completed our systematic search was also consistent with our
findings showing highest adherence to ACEIs and ARBs and lowest to diuretics.37
Implications
Although rates of blood pressure control are improving in the US, more than half of
hypertensive Americans continue to have their blood pressure above recommended levels1
and poor adherence to antihypertensives remains an important cause of poor blood pressure
control.38, 39 Lack of adherence to antihypertensive treatment has been associated with
complications including increased cardiovascular events and health care costs.40, 41 Our
findings remind us that it is important for clinicians to pay attention to adherence regardless
of antihypertensive drug class as rates of adherence were suboptimal for all drug classes.
Clinicians should pay special attention to adherence in patients who are prescribed diuretics
and beta-blockers. Incorporating objective data from pharmacy refill claims or other sources
may assist clinicians with assessing medication adherence and with optimizing their
antihypertensive prescribing decisions.42 Clinical trials that simulate real-world settings as
much as possible should be pursued to assess whether differences in adherence by drug class
are associated with differences in blood pressure control and related clinical outcomes.
Clinical Summary
More than half of US individuals with hypertension continue to have their blood pressure
above recommended levels and poor adherence to antihypertensives remains an
important cause of poor blood pressure control. Observational studies suggest that there
may be important differences in adherence to antihypertensives in distinct drug classes.
Yet, the literature describing the association between drug class and adherence is
characterized by a wide variety of patient populations, drug class comparisons, and
definitions of adherence. This heterogeneity has made it difficult to make firm
conclusions about the clinical relevance of differences in adherence according to drug
class. Accordingly, we performed a meta-analysis to determine the impact of
antihypertensive drug class on adherence to blood pressure medications. We found that
there was a significant relationship between adherence and antihypertensive drug class.
When compared to patients prescribed diuretics and beta-blockers, the drug classes
associated with the lowest adherence, patients prescribed angiotensin II receptor blockers
were approximately twice as likely to have good adherence. Overall, angiotensin-
converting enzyme inhibitors appeared to have the second best level of adherence,
followed by calcium-channel blockers, although insufficient data was available for
definitive rankings. Our findings demonstrate that it is important for clinicians to pay
attention to adherence regardless of drug class as adherence was suboptimal for all drug
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classes, and that clinicians should pay special attention to adherence in patients who are
prescribed diuretics and beta-blockers.
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Adherence to angiotensin receptor blockers compared to other antihypertensive drug classes:
meta-analysis results. Hazard ratios and odds ratios with 95% confidence intervals on a
logarithmic scale for individual or pooled study data for relative risk of adherence between
pairs of classes of blood pressure medication. Black boxes refer to studies in which
adherence is measured as persistence; red boxes refer to studies in which adherence is
measured as compliance.
Adjustments: (1) age, (2) sex, (3) race/ethnicity, (4) income or receipt of social assistance,
(5) residence, (6) comorbidity types, (7) comorbidity burden, (8) treatment with medication
classes other than antihypertensives, (9) medication regimen characteristics (number of
medications, frequency of dosing, number of pills per day), (10) health care utilization (prior
hospitalizations, physician visits, use of other services), (11) out-of-pocket medication costs,
(12) type of health insurance, (13) physician characteristics, (14) blood pressure at baseline,
(15) year of first prescription, (16) family history of comorbidities
Abbreviations: ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme
inhibitor; BB, beta-blocker; CCB, calcium-channel blocker; CI, confidence interval
Kronish et al. Page 13














Adherence to diuretics compared to other antihypertensive drug classes: meta-analysis
results. Hazard ratios and odds ratios with 95% confidence intervals on a logarithmic scale
for individual or pooled study data for each pair-wise comparison for relative risk of
adherence between pairs of classes of blood pressure medication. Black boxes refer to
studies in which adherence is measured as persistence; red boxes refer to studies in which
adherence is measured as compliance.
Adjustments: (1) age, (2) sex, (3) race/ethnicity, (4) income or receipt of social assistance,
(5) residence, (6) comorbidity types, (7) comorbidity burden, (8) treatment with medication
classes other than antihypertensives, (9) medication regimen characteristics (number of
medications, frequency of dosing, number of pills per day), (10) health care utilization (prior
hospitalizations, physician visits, use of other services), (11) out-of-pocket medication costs,
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(12) type of health insurance, (13) physician characteristics, (14) blood pressure at baseline,
(15) year of first prescription, (16) family history of comorbidities
Abbreviations: ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme
inhibitor; BB, beta-blocker; CCB, calcium-channel blocker; CI, confidence interval
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